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Abstract
Pharmacodynamic modeling has been increasingly used as a decision support tool to guide dosing regimen selection, both
in the drug development and clinical settings. Killing by antimicrobial agents has been traditionally classified categorically
as concentration-dependent (which would favor less fractionating regimens) or time-dependent (for which more frequent
dosing is preferred). While intuitive and useful to explain empiric data, a more informative approach is necessary to provide
a robust assessment of pharmacodynamic profiles in situations other than the extremes of the spectrum (e.g., agents which
exhibit partial concentration-dependent killing). A quantitative approach to describe the interaction of an antimicrobial
agent and a pathogen is proposed to fill this unmet need. A hypothetic antimicrobial agent with linear pharmacokinetics is
used for illustrative purposes. A non-linear functional form (sigmoid Emax) of killing consisted of 3 parameters is used. Using
different parameter values in conjunction with the relative growth rate of the pathogen and antimicrobial agent
concentration ranges, various conventional pharmacodynamic surrogate indices (e.g., AUC/MIC, Cmax/MIC, %T.MIC) could
be satisfactorily linked to outcomes. In addition, the dosing intensity represented by the average kill rate of a dosing
regimen can be derived, which could be used for quantitative comparison. The relevance of our approach is further
supported by experimental data from our previous investigations using a variety of gram-negative bacteria and
antimicrobial agents (moxifloxacin, levofloxacin, gentamicin, amikacin and meropenem). The pharmacodynamic profiles of a
wide range of antimicrobial agents can be assessed by a more flexible computational tool to support dosing selection.
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Introduction
Microbial resistance is rising at an alarming rate, rendering
many antimicrobial agents ineffective. There is an ever demanding
need to develop new antimicrobial agents and optimize available
agents to curb the rising resistance prevalence. There are
experimental and clinical evidence that dosing exposure could
have an impact on patient outcomes and the development of
resistance [1,2]. As a result, pharmacodynamic modeling has been
increasingly used as a decision support tool to guide dosing
selection in new drug development [3].
Microbial killing by unbound antimicrobial agents has been
traditionally classified categorically as concentration-dependent or
time-dependent. The pharmacodynamics of many antimicrobial
agents are well accepted to be linked to surrogate indices such as
peak concentration (Cmax)/minimum inhibitory concentration
(MIC), area under the concentration-time profile (AUC)/MIC or
the proportion of dosing interval in which the concentration is
above the MIC (%T.MIC) [4]. Dosing regimen design could be
based on results from traditional dose fractionation studies [5–7].
As long as the pharmacokinetics of the antimicrobial agent is
linear, the entire daily dose could be given once daily, half the
daily dose given twice daily, one-third the daily dose given three
times each day, etc. to achieve a similar daily AUC. Depending on
the difference in outcomes observed (if any), different categorical
pharmacodynamic characterization could be deduced. For
instance, if the once-daily regimen is the most effective, Cmax/
MIC would be most likely linked to outcomes. If the most frequent
dosing regimen is found to be the most beneficial, %T.MIC [or
minimum concentration (Cmin)/MIC] would likely be the most
useful pharmacodynamic surrogate index predicting outcomes. If
all the dosing regimens are similar, AUC/MIC would be deemed
to be associated with outcomes. This traditional approach has
been applied in a wide range of infection types, patient groups and
duration of therapy [1]; heterogeneous bacterial populations at the
infection site have also been considered [8].
While the dose fractionation design is intuitive and commonly
used, there may be situations where such a categorical approach to
pharmacodynamic assessment is overly restrictive. It is especially
so with new drugs (or drug classes) with complex pharmacokinetics
and pharmacodynamics. We propose an alternative approach to
pharmacodynamic characterization of the interaction between an
antimicrobial agent and a pathogen. Instead of relying on time-
dependent endpoints such as Cmax or MIC, the time course of a
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exposure is captured by a dynamic mathematical model. The
advantages of such a modeling approach have been reviewed
previously [3,9]. The proposed pharmacodynamic characteriza-
tion can be subsequently linked to a novel computational method
to derive the dosing intensity of a dosing regimen, which would
facilitate objective comparison of various dosing regimens [10]. To
illustrate our approach in the clearest way possible, a hypothetic
drug is used via a series carefully constructed computer
simulations. The relevance of our approach is subsequently
supported by application to several experimental datasets we have
reported in the past.
Methods
Basic assumptions
A hypothetic drug is used for illustrative purposes. The
pharmacokinetics of this drug is linear and characterized by a
one-compartment intravenous bolus model. The volume of
distribution of this drug is 20 liters, with an elimination half-life
of 1 hour and negligible protein binding. A daily dose of 6000 mg
can be given once daily (6000 mg q24h), twice daily (3000 mg
q12h) or 4 times daily (1500 mg q6h). The respective serum
concentration-time profiles and exposures achieved are as shown
in Figure 1 and Table 1. In addition, the target pathogen is
assumed to have a growth rate (Kg) of 1.0 h
21 (microbial doubling
time of approximately 42 minutes); resistance is not expected to
incur a significant biofitness cost (no change in bacterial growth
rate over time).
General experimental design
Details of the experimental setup have been reported previously
[11–13]. Briefly, a heterogeneous bacterial inoculum (consists of
multiple sub-populations associated with different susceptibility - a
function of the total bacterial burden and the mutational
frequency to resistance of the isolate being studied) is exposed to
different and escalating drug concentrations; the drug concentra-
tion in each experiment is constant over time. Serial samples are
taken from various flasks over 24 hours to determine viable
bacterial burden by quantitative cultures. A dynamic mathemat-
ical model is fit to the data to derive the best-fit model parameter
estimates. The growth rate of the target pathogen can be derived
from placebo control experiments. Regrowth observed after an
initial decline in bacterial burden is attributed to adaptation of the
bacterial population under a selective pressure (i.e., enrichment of
Author Summary
Antimicrobial agents have been the mainstay of treatment
for a variety of infectious diseases such as urinary tract
infections and pneumonia. Due to the increasing incidence
of antimicrobial resistance, there is an ever demanding
need to develop new antimicrobial agents rapidly. These
agents can be given in different ways, both in terms of the
daily dose and dosing frequency. The traditional approach
to the design of antimicrobial agent dosing regimen relies
primarily on a categorical classification, which often could
be restrictive. We proposed a new computational method
to provide quantitative insights to the interaction between
an antimicrobial agent and a pathogen (pharmacodynam-
ics). With a more robust understanding of this relationship,
the effectiveness of different antimicrobial dosing regi-
mens can be compared efficiently, which would facilitate
new agent development by rationally guiding dosing
regimen selection. The relevance of our approach was
supported by a series of experimental validation using
different antimicrobial agents and bacteria. A higher
probability of resistance suppression could be achieved
with optimal dosing regimens, which may prolong the
clinical utility of new agents under development.
Figure 1. Dose fractionation designs of an identical daily dose.
doi:10.1371/journal.pcbi.1001043.g001
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resistance emergence during therapy). It should be stressed that
the term ‘adaptation’ is used here to denote adaptation at the
population level, not at the individual cell level (e.g., through
induction of efflux pumps or beta-lactamases). Namely, the entire
population adapts because of a selective pressure. Various specific
mathematical structures have been used, an example is shown in
one of our previous work [12]. Using the pharmacodynamic
profile of the most resistant cell in the population (i.e., the killing
function when tR‘), assessments are made as to which of the
proposed dosing regimens (detailed above) would have the greatest
bactericidal activity. A dosing regimen with a greater average kill
rate is expected to have a higher probability of suppressing the
development of resistance over time, when the majority of the
population can be controlled. Subsequently, the same inoculum of
bacteria is exposed to various fluctuating drug concentration-time
profiles in a hollow-fiber infection model. Experimentally observed
bacterial responses are used to support the validity the categorical
predictions of the mathematical model.
Mathematical modeling
The saturable killing rate of an antimicrobial agent is
characterized by a sigmoid Emax model, commonly used in
many investigations [8,14–18]. A new computational approach is
proposed to facilitate objective comparison. The average kill rate
of a dosing regimen can be conceptualized as the dosing intensity.
It is derived by converting instantaneous drug concentration to
instantaneous kill rate using the parameter estimates of the kill
function, and subsequently integrating all instantaneous kill rates
with respect to time over a dosing interval [19].
D~
1
t
ðt
0
Kk:C(t)
H
C(t)
HzC50
Hdt
where D{dosing intensity (average kill rate)
t{dosing interval
Kk{maximum kill rate
C(t){ concentration of antimicrobial agent at time t
H{sigmoidicity of the kill function
C50{concentration of antimicrobial agent to
achieve 50% maximal kill rate
The average kill rate can be used quantitatively to compare the
effectiveness of various dosing regimens, in relation to the growth
rate of the target pathogen. This approach assumes eradication of
the bacterial population cannot be achieved within one dosing
interval; a large killing rate shortly after dose administration is as
important as a large killing rate towards the end of the dosing
interval. The importance of the average kill rate (D) is that
complete eradication of the entire bacterial population and
prevention of resistance emergence will be observed, if D.Kg for
the most resistant cell in the population. The preceding statement
assumes that no physiological changes (e.g., induction of efflux
pumps or beta-lactamases) take place in bacteria as a result of
exposure to the antimicrobial agent. All simulations were
performed using the ADAPT II program [20], and graphs were
plotted with Mathematica 6.0 (Wolfram Research, Inc., Cham-
paign, IL).
Results
Pharmacodynamic profiles
Using the same structural form, three typical pharmacodynamic
profiles can be shown (Figures 2–4). These distinct pharmacody-
namic profiles are characterized by 3 parameter estimates and
represent unique (extreme) situations. In reality, intermediate
profiles (e.g., partially concentration dependent killing) are also
possible and could be objectively described by these parameter
estimates. The growth rate of the target pathogen is shown
concurrently for comparison. Finally, the concentration ranges of
antimicrobial agent attained by different dosing regimens are also
shown in each situation.
In Figure 2, the maximal killing rate is significantly higher than
the growth rate of the target pathogen. The concentration-effect
relationship is also fairly linear in the concentration ranges
achieved by all the dosing regimens. Therefore, attaining a high
concentration for a brief period of time would not be much more
advantageous, as compared to lower concentrations for a more
prolonged time frame. As a result, dosing frequency is not
expected to have a huge impact of the overall bactericidal activity,
as long as the daily dose is kept constant. Using conventional
nomenclature, this pharmacodynamic profile is concentration
dependent killing, and AUC/MIC would be considered the most
important. This pattern is consistent with our experience with data
reported for moxifloxacin [21] and levofloxacin against Escherichia
coli (unpublished data).
In Figure 3, the maximal killing rate is still significantly higher
than the growth rate of the target pathogen. However, the
concentration-effect relationship is non-linear in the concentration
range achieved by the dosing regimens. The killing rate rises
sharply beyond a certain threshold (i.e., approximately 75 mg/l -
the peak concentration of the q6h dosing regimen). A dosing
regimen attaining a concentration beyond this threshold could
encounter a more than proportional increase in killing rate, even
for a brief period of time. Consequently, less frequent dosing (to
achieve a concentration transiently above the threshold) is
expected to result in a greater overall bactericidal activity. Using
conventional nomenclature, this pharmacodynamic profile is
concentration dependent killing, and Cmax/MIC would be
considered the most important.
An important point should be raised here. The above example
is illustrated with only one daily dose (6000 mg daily). Using a
qualitative (yes / no) outcome assessment (e.g., mortality, clinical
cure, resistance suppression), different categorical interpretations
may be arrived at with the same pharmacodynamic profile. To
further exemplify this point, the average kill rate is graphed as a
function of both daily dose and dosing interval, using a 3-
dimensional surface response as detailed previously [22]. In
addition, a cross sectional view is undertaken when the average kill
Table 1. Dose fractionation designs of an identical daily dose.
Dosing regimen Cmax (mg/l) AUC24 (mg.h/l) % T.4mg/l
6000 mg q24h 300 433 25
3000 mg q12h 150 433 42
1500 mg q6h 75 433 67
Note: AUC24 may not be identical in drugs with an elimination half-life of
$4 hours. The discrepancy is due residual drug at the end of the 24 hour
period, which is more prominent with a drug of long half-life. One simple way
to circumvent the discrepancy is to focus on AUC 0–infinity (total cumulative
exposure) instead of AUC 0–24.
doi:10.1371/journal.pcbi.1001043.t001
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21).
When the average kill rate of a dosing regimen is greater than the
growth rate of the target pathogen (i.e., D.Kg), resistance
suppression is generally anticipated. On the other hand, if the
average kill rate of a dosing regimen is less than the growth rate of
the target pathogen (i.e., D,Kg), resistance amplification is
expected over time. Given that AUC and Cmax are highly
correlated in clinical or animal studies (where drug clearance
cannot be easily modified), it may be difficult to discriminate
whether AUC/MIC or Cmax/MIC is the pharmacodynamic
variable most closely linked to outcomes. Our analysis revealed
that there could be experimental evidence supporting both
conclusions in the same antimicrobial agent-pathogen combina-
tion. The daily dose(s) to be examined in fractionation studies
should also be carefully considered in the analysis. The dose
exposure used may not be the same for different outcomes (e.g.,
survival, 1-log drop in microbial burden, or resistance suppres-
sion), and thus may have contributed (at least partially) to
enthusiastic debates in the literature [23–26]. Other investigators
have also reported different pharmacodynamic characterization at
different dose levels of the same drug. Fractionation of the
minocycline dose at the human dose equivalents showed no
difference between once, twice, or three times a day dosing against
Staphylococcus aureus (i.e., AUC/MIC was the most important). In
contrast, fractionation of the dose with a static effect indicated that
once daily dosing was superior (i.e., Cmax/MIC was the most
important) [27]. In addition, these conflicting patterns are also
consistent with our own experience examining the pharmacody-
namics of the aminoglycosides. Using a dose fractionation design,
there were data to support gentamicin AUC/MIC was the most
important against Pseudomonas aeruginosa [11]; but amikacin Cmax/
MIC appeared to be the most important against Acinetobacter
baumannii [13].
Finally in Figure 4, the maximal killing rate is only slightly
higher than the growth rate of the target pathogen. The
concentration-effect relationship is non-linear in the concentra-
tion range achieved by the dosing regimens, but the threshold
which the killing rate rises sharply (i.e., approximately 5 mg/l)
Figure 2. Concentration dependent killing; AUC/MIC most important. Kk=60.0 h
21. C50=600.0 mg/l. H=1.0. Black solid line depicts the
relationship between drug concentration and killing rate; black dotted line represents the microbial growth rate. Arrows below represent
concentration ranges achieved with various dosing regimens (red – once daily; green – twice daily; blue – four times daily). Two intersecting planes
are shown: a translucent surface and an opaque mesh surface (where the average kill rate=1.0 h
21). The 3-dimensional mesh surface is made up of a
collection of data points; each datum point is characterized by a value on the x, y and z axes, corresponding to the daily dose (x), dosing interval (y)
and average kill rate (z). For a dosing regimen to suppress resistance development, it is imperative that the average kill rate (D) is more than the
growth rate (Kg) of the target pathogen. To identify promising dosing regimens (combinations of dose and dosing interval) to suppress resistance
development, D must be greater than Kg (the region where the translucent surface is above the opaque mesh plane). White area depicts dosing
regimens (combinations of daily dose and dosing interval which the average kill rate is .1.0 h
21. Using a daily dose of 6000 mg, the average kill rates
for different regimens are: 1.463 h
21 (q24h), 1.610 h
21 (q12h), and 1.690 h
21(q6h).
doi:10.1371/journal.pcbi.1001043.g002
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circumstances, a transiently high concentration achieved in a less
frequent dosing regimen does not translate to a higher kill rate,
and killing is compromised when the concentration falls below
the threshold for a prolonged period of time. Consequently, a
more rational dosing strategy is to maintain concentrations above
the threshold for as long as possible. Using conventional
nomenclature, this pharmacodynamic profile is time dependent
killing, and %T.MIC (or Cmin/MIC) would be considered the
most important when the investigations are performed in the
‘critical’ daily dose range. In the extremes of the daily dose range
(i.e., more than 14000 mg or less than 2000 mg daily), AUC/
MIC could still be interpreted as an important surrogate index
linked to outcomes observed. This pattern is consistent with our
experience with data reported for meropenem against Pseudomonas
aeruginosa [28].
Discussion
In all 3 typical pharmacodynamic profiles described, the same
structural form of killing rate was used (a sigmoid Emax model).
Different profiles were simply reflected in the values of the model
parameters, which could be derived from actual experimental data
observed between an antimicrobial agent and a pathogen within a
short timeframe (e.g., 24 hours). Of note, knowledge of specific
mechanism(s) of resistance was not necessary as inputs. As shown
above, an antimicrobial agent can be shown to exhibit both
concentration and time-dependent killing, but the proposed model
was flexible enough to describe different distinct pharmacody-
namic profiles (and any intermediates in between).
Antimicrobial kill kinetics has been previously examined using a
related approach. In one study, concentration dependency of
bacterial killing was primarily attributed to the sigmoidicity
Figure 3. Concentration dependent killing; Cmax/MIC most important. Kk=40.0 h
21. C50=100.0 mg/l. H=4.0. Black solid line depicts the
relationship between drug concentration and killing rate; black dotted line represents the microbial growth rate. Arrows below represent
concentration ranges achieved with various dosing regimens (red – once daily; green – twice daily; blue – four times daily). White area depicts dosing
regimens (combinations of daily dose and dosing interval which the average kill rate is .1.0 h
21. Using a daily dose of 6000 mg, the average kill rates
for different regimens are: 2.650 h
21 (q24h), 2.168 h
21 (q12h), and 0.689 h
21(q6h). Using a conventional dose fractionation design with 16000 mg
daily (e.g., 16000 mg q24h, 8000 mg q12h, 4000 mg q6h, etc.), all regimens are expected to suppress the bacterial population, thus AUC/MIC is likely
to be concluded as the pharmacodynamic index associated with resistance suppression. In addition, if a daily dose of 2000 mg is selected (e.g.,
2000 mg q24h, 1000 mg q12h, 500 mg q6h, etc.), all regimens are expected to be associated with regrowth, and therefore AUC/MIC is also likely to
be deemed as the pharmacodynamic index associated with resistance development. However, if a daily dose of 6000 mg is chosen (e.g., 6000 mg
q24h, 3000 mg q12h, 1500 mg q6h, etc.), a less frequent dosing regimen (e.g., q24h) is anticipated to have a higher likelihood of suppressing
resistance, and as such Cmax/MIC is likely to be concluded as the pharmacodynamic index associated with resistance suppression. Therefore, the
strict use of surrogate indices in pharmacodynamic modeling is not always optimal as they may be subjected to selection basis of the concentration
range examined.
doi:10.1371/journal.pcbi.1001043.g003
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tion-dependent killing was associated with a low sigmoidicity
constant. In our opinion, all drugs exhibit concentration-
dependent killing in the concentration range corresponding to
20%–80% of maximal killing rate (regardless of the magnitude of
sigmoidicity). It is equally important to consider Kk and C50,i n
order to get a complete and accurate pharmacodynamic
assessment of an antimicrobial agent. As reviewed previously by
Czock et al [30], the effect of the sigmoidicity constant could be
influenced by the ratio of Kk/Kg (similar illustrations were also
shown in Figures 3 and 4). In addition, whether such
concentration-dependent killing is clinically relevant is further
dependent on whether the concentration-dependent killing
concentration range is achievable in humans with acceptable
toxicity, potentially resulting in other categorical descriptions on a
continuous spectrum such as ‘‘partially concentration-dependent’’
(where there is partial overlap of the concentration ranges) or
‘‘time-dependent’’ killing (where there is minimal overlap of the
concentration ranges). Thus C50 is also not irrelevant as pointed
out previously [30]. Consequently, we resorted to a more
comprehensible approach by taking into consideration additional
pertinent variables. We attempted to develop a more robust
computational tool covering a wider spectrum of relevant
scenarios in new drug development.
To extend these pharmacodynamic concepts previously re-
viewed, we put forth herein a novel concept to derive the dosing
intensity of a dosing regimen by comparing the average killing rate
to the growth rate of the target pathogen. A similar approach was
proposed in linking pharmacokinetics to drug effects in circular /
proliferative systems using the concept of reproduction minimum
inhibitory concentration (RMIC) and equivalent effective constant
concentration (ECC) [31]. As we have shown in Figure 2, in the
unique case of linear concentration-effect relationship, the
heuristics proposed previously (RMIC and ECC) would be
identical. Dosing frequency is not expected to have a major
impact of effectiveness, as long as the daily dose is kept constant
(i.e., AUC/MIC is the most important). To highlight a common
drawback in conventional modeling, our computational tool
illustrated the pharmacokinetic / pharmacodynamic concepts via
several theoretical and experimental case examples.
We believe our proposed approach would enhance the
applicability of these concepts in drug development and clinical
settings. Specifically, the pharmacodynamics of antimicrobial
agents are characterized as a continuum (as opposed to discrete
Figure 4. Time dependent killing; %T.MIC most important. Kk=4.0 h
21. C50=10.0 mg/l. H=4.0. Black solid line depicts the relationship
between drug concentration and killing rate; black dotted line represents the microbial growth rate. Arrows below represent concentration ranges
achieved with various dosing regimens (red – once daily; green – twice daily; blue – four times daily). White area depicts dosing regimens
(combinations of daily dose and dosing interval which the average kill rate is .1.0 h
21. Using a daily dose of 6000 mg, the average kill rates for
different regimens are: 0.818 h
21 (q24h), 1.303 h
21 (q12h), and 1.950 h
21(q6h).
doi:10.1371/journal.pcbi.1001043.g004
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methods to be applied. The efficiency to objectively compare the
effectiveness of a large number of dosing regimens (to be
investigated in pre-clinical or clinical studies) would be improved
as a result. Furthermore, we have also justified our rationale using
supportive data derived under more clinically relevant experi-
mental conditions (multiple sets of experimental data involving
fluctuating drug concentrations over at least 72 hours, as shown in
Table 2). Such an approach provides a fresh perspective on our
understanding of antimicrobial agent pharmacodynamics; the new
insights could resolve heated debates in the literature relating to
which pharmacodynamic surrogate index is the most closely
related to outcomes.
In this study, the mathematical model used was to characterize
the behavior of a heterogeneous bacterial inoculum, which consists
of multiple sub-populations associated with different susceptibility.
This modeling approach (involving a time-variant parameter to
account for adaptation of the bacterial population) would enable
us to better capture regrowth and / or emergence of resistance
over time. Nonetheless, the mathematical model is flexible and can
be modified easily to accommodate a homogeneous inoculum by
not allowing C50 (an index of bacterial population susceptibility) to
increase over time (no adaptation). Regardless of the approach
used, fundamental limitations in dose fractionation design and
categorical pharmacodynamic classification of antimicrobial
agents would still remain. However, the model does not account
for the immune system (which may play an important role against
small resistant populations) and bacterial stress response not
observed during the initial observation period. Both issues
(modeling the effect of the immune system and temporal bacterial
response leading to resistance) are currently under investigation.
In summary, pharmacodynamic modeling is an important
decision-support tool to guide the selection of dosing regimens.
The use of surrogate pharmacodynamic indices has taught us
much on the differences in the killing profiles of different
antimicrobial agents, resulting in several rational dosing strategies
to optimize patient outcomes. As we are dealing with drugs with
more complex pharmacokinetics and pharmacodynamics, it is also
clear that using simple surrogate pharmacodynamic indices may
not always be informative enough to make good decisions to
dosing selection. In the interest of further accelerating new drug
development and for the benefits of our patients, alternative
modeling and computational approaches, such as the one
proposed herein should be explored.
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